White blood cell inactivation after treatment with riboflavin and ultraviolet light

被引:69
作者
Marschner, Susanne
Fast, Loren A.
Baldwin, William M., III
Slichter, Sherrill J.
Goodrich, Raymond P. [1 ]
机构
[1] CaridianBCT Biotechnol LLC, Lakewood, CO 80215 USA
基金
美国国家卫生研究院;
关键词
PATHOGEN REDUCTION TECHNOLOGY; VERSUS-HOST-DISEASE; B IRRADIATION; TRANSFUSION REACTIONS; PLATELET TRANSFUSIONS; PLASMA; PRODUCTS; LEUKOREDUCTION; QUALITY; FEBRILE;
D O I
10.1111/j.1537-2995.2010.02714.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Functional white blood cells (WBCs) in blood components may be responsible for a number of adverse transfusion effects, including transfusion-associated graft-versus-host disease (TA-GVHD), alloimmunization, and alloimmune platelet (PLT) refractoriness. TA-GVHD occurs when functional lymphocytes are transfused into a patient who is unable to mount an immune response to the human leukocyte antigen (HLA) due to HLA compatibility or immunosuppression Alloantibodies against HLA antigens on donor WBCs and PLTs are the major. cause of refractoriness to PLT transfusions in patients receiving repeated blood transfusions. Attempts to reduce these undesirable effects have included leukoreduction filters and gamma irradiation Studies have shown that exposure of PLT concentrates to riboflavin and light (Mirasol pathogen reduction technology [PRT], CaridianBCT Biotechnologies) causes irreparable modifications of nucleic acids that result in inactivation of a wide range of pathogens as well as inhibition of the immunologic responses mediated by WBCs present in PLT concentrates. This article summarizes these studies and also reports on additional findings from the Trial to Reduce Alloimmunization to Platelets (TRAP) and Mirasol Clinical Evaluation (MIRACLE) trials. Data from in vitro studies and this clinical trial suggest that PRT treatment may be as effective as gamma irradiation in preventing TA-GVHD and more effective than leukoreduction in preventing alloimmunization.
引用
收藏
页码:2489 / 2498
页数:10
相关论文
共 46 条
  • [1] Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants
    Asano, Hiroshi
    Lee, Chih-Yuan
    Fox-Talbot, Karen
    Koh, Cheryl M.
    Erdinc, Melek M.
    Marschner, Susanne
    Keil, Shawn
    Goodrich, Raymond P.
    Baldwin, William M., III
    [J]. TRANSPLANTATION, 2007, 84 (09) : 1174 - 1182
  • [2] Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
    AuBuchon, JP
    Herschel, L
    Roger, J
    Taylor, H
    Whitley, P
    Li, JZ
    Edrich, R
    Goodrich, RP
    [J]. TRANSFUSION, 2005, 45 (08) : 1335 - 1341
  • [3] QUALITY OF PLATELET CONCENTRATES IRRADIATED WITH UVB LIGHT - EFFECT OF UV DOSE AND DOSE-RATE ON GLYCOCALICIN RELEASE AND CORRELATION WITH OTHER MARKERS OF THE PLATELET STORAGE LESION
    BESSOS, H
    MURPHY, WG
    ROBERTSON, A
    VICKERS, M
    SEGHATCHIAN, MJ
    TANDY, NP
    CUTTS, M
    PAMPHILON, DH
    [J]. TRANSFUSION MEDICINE, 1993, 3 (02) : 115 - 121
  • [4] Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse?
    Blajchman, MA
    [J]. TRANSFUSION, 1999, 39 (07) : 665 - 670
  • [5] Blajchman Morris A, 2002, Am J Ther, V9, P389, DOI 10.1097/00045391-200209000-00005
  • [6] Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light
    Cardo, Lisa J.
    Salata, Jeanne
    Mendez, Juan
    Reddy, Heather
    Goodrich, Raymond
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (02) : 131 - 137
  • [7] Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light
    Cardo, LJ
    Rentas, FJ
    Ketchum, L
    Salata, J
    Harman, R
    Melvin, W
    Weina, PJ
    Mendez, J
    Reddy, H
    Goodrich, R
    [J]. VOX SANGUINIS, 2006, 90 (02) : 85 - 91
  • [8] Carson JL, 2004, CAN J ANAESTH, V51, P407, DOI 10.1007/BF03018300
  • [9] A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology
    Cazenave, J. -P
    Follea, G.
    Bardiaux, L.
    Boiron, J. -M.
    Lafeuillade, B.
    Debost, M.
    Lioure, B.
    Harousseau, J. -L.
    Tabrizi, R.
    Cahn, J. -Y
    Michallet, M.
    Ambruso, D.
    Schots, R.
    Tissot, J. -D.
    Sensebe, L.
    Kondo, T.
    McCullough, J.
    Rebulla, P.
    Escolar, G.
    Mintz, P.
    Heddle, N. M.
    Goodrich, R. P.
    Bruhwyler, J.
    Le, C.
    Cook, R. J.
    Stouch, B.
    [J]. TRANSFUSION, 2010, 50 (11) : 2362 - 2375
  • [10] Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products
    Coppage, Myra
    Baker, Marc
    Fialkow, Lawrence
    Meehan, Danielle
    Gettings, Kelly
    Chen, Leway
    Massey, H. Todd
    Blumberg, Neil
    [J]. HUMAN IMMUNOLOGY, 2009, 70 (06) : 413 - 416